Medically reviewed by a licensed healthcare professional. Last updated March 2026.
Key Takeaways
- The FDA approved an oral semaglutide tablet for weight loss in December 2025, offering a needle-free alternative to the Wegovy injection [1].
- Clinical trials show the oral formulation produces meaningful weight loss, though direct comparison data with the injection is still limited.
- Oral Wegovy is priced at $149-$299/month through select programs — significantly less than the injection at $499/month (NovoCare) [2].
- The pill must be taken daily on an empty stomach with minimal water, which requires more discipline than a weekly injection.
- Both formulations contain the same active ingredient (semaglutide) but use different delivery systems.
What Changed: The Oral Option
For years, GLP-1 medications for weight loss were injection-only. That changed in December 2025 when the FDA approved an oral semaglutide tablet for chronic weight management [1]. This was a significant development for the estimated 20-30% of potential patients who avoid GLP-1 therapy specifically because of needle aversion.
The oral tablet uses a technology called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) that enhances absorption of the peptide through the stomach lining [3]. Without this absorption enhancer, semaglutide would be broken down by digestive enzymes before reaching the bloodstream.
Comparing the Two Formulations
| Feature | Oral Wegovy (Pill) | Injectable Wegovy (Shot) |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Administration | Daily tablet | Weekly injection |
| Dose escalation | Gradual over 4+ months | Gradual over 4+ months |
| Target dose | 50 mg daily | 2.4 mg weekly |
| Self-pay price | $149-$299/mo | $499/mo (NovoCare) |
| Needle required | No | Yes |
| Empty stomach required | Yes (30 min before food) | No |
| Storage | Room temperature | Refrigerated |
| FDA approved for weight loss | Yes (Dec 2025) | Yes (June 2021) |
Efficacy: How Do Results Compare?
Injectable Semaglutide Data (STEP 1)
The injectable formulation has robust clinical trial data from the STEP program [4]:
- Average weight loss: 14.9% over 68 weeks
- 86% achieved at least 5% weight loss
- 50% achieved at least 15% weight loss
Oral Semaglutide Data
Clinical trials for the oral weight loss formulation demonstrated clinically significant weight loss. The OASIS 1 trial evaluated oral semaglutide 50 mg daily in adults with obesity [5]:
- Average weight loss: approximately 15-17% over 68 weeks
- Results were comparable to the injectable formulation
The oral formulation appears to produce similar weight loss to the injection, though head-to-head comparison trials in the weight loss indication are limited.
Practical Differences
Daily Pill vs. Weekly Shot
This is often the deciding factor for patients:
Oral Wegovy requires:
- Taking a pill every morning on a completely empty stomach
- Swallowing with no more than 4 ounces (120 mL) of plain water
- Waiting at least 30 minutes before eating, drinking, or taking other medications
- Daily consistency — missing days reduces effectiveness
Injectable Wegovy requires:
- One injection per week (same day each week)
- Self-injection into the abdomen, thigh, or upper arm
- Proper storage (refrigerated before first use)
- No dietary timing restrictions
Which is easier? It depends on your lifestyle. If you have a consistent morning routine and don't mind the fasting requirement, the pill may be more convenient. If you'd rather deal with treatment once a week and not think about it daily, the injection may be simpler despite the needle.
Side Effect Differences
Both formulations share similar GI side effects (nausea, diarrhea, constipation) since the active ingredient is the same [4][5]. However:
- Oral-specific considerations: Some patients report more upper GI symptoms (heartburn, stomach discomfort) with the oral form, likely related to the stomach absorption mechanism
- Injection-specific considerations: Mild injection site reactions (redness, itching) occur in approximately 3-5% of patients
Cost Comparison
The pricing difference is significant and may be the most compelling factor for many patients:
| Option | Monthly Cost | Annual Cost |
|---|---|---|
| Oral Wegovy (self-pay programs) | $149-$299 | $1,788-$3,588 |
| Injectable Wegovy (NovoCare) | $499 | $5,988 |
| Injectable Wegovy (list price) | ~$1,349 | ~$16,188 |
Oral Wegovy at $149/month represents approximately a 70% cost reduction compared to the NovoCare injection price. This pricing has made semaglutide accessible to patients who previously couldn't afford treatment.
Insurance coverage for the oral formulation is still evolving. Some plans that cover injectable Wegovy also cover the oral version; others have not yet added it to their formulary. Check with your specific plan.
Who Should Choose the Pill?
The oral formulation may be better if you:
- Have a fear of needles or injection anxiety
- Want the lowest-cost branded semaglutide option
- Have a consistent morning routine compatible with the fasting requirement
- Prefer the simplicity of taking a daily pill
- Travel frequently (no need for cold-chain storage or carrying syringes)
Who Should Choose the Injection?
The injection may be better if you:
- Prefer once-weekly dosing over daily
- Have irregular morning schedules or can't reliably fast before breakfast
- Take other morning medications that can't be delayed 30 minutes
- Have upper GI conditions (GERD, gastritis) that might worsen with oral absorption
- Want the formulation with the longest clinical track record
Switching Between Formulations
If you're currently on injectable Wegovy and want to switch to oral (or vice versa), work with your provider on the transition. The dose equivalency between oral and injectable semaglutide requires medical guidance — you can't simply convert one to the other without professional oversight.
Discuss your options with a GLP-1 provider near you or explore telehealth platforms that offer both formulations.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you are experiencing a medical emergency, call 911.
Sources
- FDA. "FDA Approves Oral Semaglutide for Chronic Weight Management." December 2025.
- Novo Nordisk. NovoCare Wegovy Pricing Programs. https://www.novocare.com/
- Buckley ST, et al. "Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist." Science Translational Medicine. 2018;10(467).
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." New England Journal of Medicine. 2021;384:989-1002.
- Knop FK, et al. "Oral Semaglutide 50 mg Taken Once Daily in Adults with Overweight or Obesity (OASIS 1)." The Lancet. 2023;402(10403):705-719.